Reve Technologies, Inc. (BSSP)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2014 | -181.08 Thousand USD | -128.97% |
| 2013 | -79.08 Thousand USD | -87.65% |
| 2012 | -42.14 Thousand USD | 52.21% |
| 2011 | -88.18 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2015 Q1 | -181.39 Thousand USD | -216.61% |
| 2015 Q2 | -201.76 Thousand USD | -11.23% |
| 2015 Q3 | -29.56 Thousand USD | 85.35% |
| 2014 Q2 | -46.11 Thousand USD | -40.83% |
| 2014 Q4 | -57.29 Thousand USD | -27.51% |
| 2014 Q3 | -44.93 Thousand USD | 2.57% |
| 2014 FY | - USD | -128.97% |
| 2014 Q1 | -32.74 Thousand USD | -18.56% |
| 2013 FY | - USD | -87.65% |
| 2013 Q4 | -27.61 Thousand USD | 9.73% |
| 2013 Q2 | -16.79 Thousand USD | -312.14% |
| 2013 Q1 | -4076.00 USD | 61.76% |
| 2013 Q3 | -30.59 Thousand USD | -82.12% |
| 2012 FY | - USD | 52.21% |
| 2012 Q3 | -9204.00 USD | -5.74% |
| 2012 Q2 | -8704.00 USD | 35.91% |
| 2012 Q1 | -13.58 Thousand USD | -73.41% |
| 2012 Q4 | -10.65 Thousand USD | -15.81% |
| 2011 Q2 | -8998.00 USD | -85.41% |
| 2011 Q1 | -4853.00 USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q3 | -66.51 Thousand USD | -639.18% |
| 2011 Q4 | -7831.00 USD | 88.23% |
| 2010 Q3 | -1038.00 USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 99.745% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 96.946% |
| SQZ Biotechnologies Company | -64.14 Million USD | 99.718% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 98.957% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 100.193% |
| Mesoblast Limited | -62.38 Million USD | 99.71% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 88.211% |
| Genus plc | 73.7 Million USD | 100.246% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 97.261% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 94.895% |
| Marizyme, Inc. | -34.28 Million USD | 99.472% |
| ContraFect Corporation | -64.99 Million USD | 99.721% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 97.936% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 95.999% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 87.082% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 93.152% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 92.207% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 65.044% |
| Accustem Sciences Inc. | -3.74 Million USD | 95.166% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 99.625% |
| EV Biologics, Inc. | -1.26 Million USD | 85.709% |
| Q BioMed Inc. | -617.62 Thousand USD | 70.68% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 105.07% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 71.365% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 92.073% |
| Biomind Labs Inc. | -1.03 Million USD | 82.496% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 101.833% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 97.471% |
| Skye Bioscience, Inc. | -13.54 Million USD | 98.663% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 87.825% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -624.352% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 95.338% |
| IMV Inc. | -35.52 Million USD | 99.49% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 98.859% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 92.762% |
| GB Sciences, Inc. | -1.41 Million USD | 87.246% |
| Alpha Cognition Inc. | -9.7 Million USD | 98.134% |
| HST Global, Inc. | -5303.00 USD | -3314.822% |
| CSL Limited | 4.78 Billion USD | 100.004% |
| Halberd Corporation | -74.27 Thousand USD | -143.794% |
| Enzolytics Inc. | -2.12 Million USD | 91.466% |
| Resverlogix Corp. | -11.74 Million USD | 98.458% |
| Affymax, Inc. | -14.29 Million USD | 98.733% |
| SYBLEU INC | -141.57 Thousand USD | -27.913% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 94.088% |
| argenx SE | -216.02 Million USD | 99.916% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 99.673% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 114.88% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 87.919% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 147.8% |
| AVAX Technologies, Inc. | -6.11 Million USD | 97.037% |
| Zenith Capital Corp. | -8.6 Million USD | 97.896% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.927% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -939.481% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 92.598% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -2.877% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 99.543% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 93.739% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 82.693% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 2793.159% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 89.652% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 90.573% |
| BioStem Technologies, Inc. | -7.55 Million USD | 97.603% |
| ONE Bio Corp. | 13.61 Million USD | 101.33% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 91.196% |
| Agentix Corp. | -1.37 Million USD | 86.799% |
| LadRx Corporation | 412.28 Thousand USD | 143.923% |
| Cell Source, Inc. | -4.27 Million USD | 95.762% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 50.687% |
| Regen BioPharma, Inc. | 1.46 Million USD | 112.353% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 80.673% |
| NovAccess Global Inc. | -1.03 Million USD | 82.5% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 102.045% |
| Itoco Inc. | -1.86 Million USD | 90.311% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 52.298% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 83.773% |
| Kadimastem Ltd | -2.62 Million USD | 93.1% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 24.278% |
| CytoDyn Inc. | -18.02 Million USD | 98.996% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -129.141% |
| Mobile Lads Corp. | -2.24 Million USD | 91.92% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -1380.808% |
| Qrons Inc. | -40.08 Thousand USD | -351.805% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 62.714% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 134.334% |
| Rebus Holdings, Inc. | -951 Thousand USD | 80.958% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 82.949% |
| International Stem Cell Corporation | 202 Thousand USD | 189.648% |
| Bioxytran, Inc. | -3.82 Million USD | 95.26% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -244.012% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 92.644% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 99.495% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -302.418% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 93.386% |
| Neutra Corp. | -181.24 Thousand USD | 0.088% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 99.102% |
| PureTech Health plc | -11.62 Million USD | 98.443% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 99.102% |
| IXICO plc | -707 Thousand USD | 74.386% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 97.644% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 99.625% |
| CSL Limited | 4.73 Billion USD | 100.004% |
| Cellectis S.A. | -92.63 Million USD | 99.805% |